

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/09, C12N 5/10, 9/00, 15/31, C12Q 1/14, C12P 21/00, C07K 14/315, 16/12	A1	(11) International Publication Number: WO 97/38722 (43) International Publication Date: 23 October 1997 (23.10.97)
(21) International Application Number: PCT/US97/06876 (22) International Filing Date: 18 April 1997 (18.04.97) (30) Priority Data: 9607993.4 18 April 1996 (18.04.96) GB (71) Applicants (for all designated States except US): SMITHK- LINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US). SMITHK- LINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): LAWLOR, Elizabeth, Jane [GB/US]; 260 Lapp Road, Malem, PA 19355 (US). (74) Agents: GIMMI, Edward, R. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: NOVEL COMPOUNDS (57) Abstract The invention provides pheS (beta) and pheS (alpha) polypeptides and DNA (RNA) encoding pheS (beta) and pheS (alpha) polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing pheS (beta) and pheS (alpha) polypeptides to screen for antibacterial compounds.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL COMPOUNDS

RELATED APPLICATIONS

This application claims benefit of UK application number 9607993.4, filed April 18, 1996.

5 FIELD OF THE INVENTION



This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, in these and in other regards, the invention relates to novel polynucleotides and polypeptides of the phenylalanyl tRNA synthetase (beta sub-unit) family, hereinafter referred to as "pheS (beta)," and the phenylalanyl tRNA synthetase (alpha sub-unit) family, hereinafter referred to as "pheS (alpha)".

BACKGROUND OF THE INVENTION

The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid. Since its isolation more than 100 years ago, *Streptococcus pneumoniae* has been one of the more intensively studied microbes. For example, much of our early understanding that DNA is, in fact, the genetic material was predicated on the work of Griffith and of Avery, Macleod and McCarty using this microbe. Despite the vast amount of research with *S. pneumoniae*, many questions concerning the virulence of this microbe remain. It is particularly preferred to employ Streptococcal genes and gene products as targets for the development of antibiotics.

The frequency of *Streptococcus pneumoniae* infections has risen dramatically in the past 20 years. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate *Streptococcus pneumoniae* strains which are resistant to some or all of the standard antibiotics. This has created a demand for both new anti-microbial agents and diagnostic tests for this organism.

The t-RNA synthetases have a primary role in protein synthesis according to the following scheme:



in which AA is an amino acid.

Inhibition of this process leads to a reduction in the levels of charged t-RNA and this triggers a cascade of responses known as the stringent response, the result of which is the induction of a state of dormancy in the organism. As such selective inhibitors of bacterial t-RNA synthetase have potential as antibacterial agents. One example of such is mupirocin which is a selective inhibitor of isoleucyl t-RNA synthetase. Other t-RNA synthetases are now being examined as possible anti-bacterial targets, this process being greatly assisted by the isolation of the synthetase.

Clearly, there is a need for factors, such as the novel compounds of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity. Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists which can play a role in preventing, ameliorating or correcting infections, dysfunctions or diseases.

The polypeptides of the invention have amino acid sequence homology to a known *Bacillus subtilis* phenylalanyl tRNA synthetase beta sub-unit protein and *Bacillus subtilis* phenylalanyl tRNA synthetase (alpha sub-unit) protein.

SUMMARY OF THE INVENTION

It is an object of the invention to provide polypeptides that have been identified as novel pheS (beta) and pheS (alpha) polypeptides by homology between the amino acid sequence set out in Table 1 [SEQ ID NO: 2, 6 respectively] and a known amino acid sequence or sequences of other proteins such as *Bacillus subtilis* phenylalanyl tRNA synthetase alpha or beta sub-unit protein.

It is a further object of the invention to provide polynucleotides that encode pheS (beta) or pheS (alpha) polypeptides, particularly polynucleotides that encode the polypeptide herein designated pheS (beta) and pheS (alpha).

In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding pheS (beta) polypeptides comprising the sequence set out in Table 1 [SEQ ID NO:1, 5], or a variant thereof.

In another particularly preferred embodiment of the invention there is a novel pheS (beta) protein from *Streptococcus pneumoniae* comprising the amino acid sequence of Table 1 [SEQ ID NO:2], or a variant thereof.

In another particularly preferred embodiment of the invention there is a novel pheS (alpha) protein from *Streptococcus pneumoniae* comprising the amino acid sequence of Table 1 [SEQ ID NO:6], or a variant thereof.

In accordance with another aspect of the invention there is provided an isolated nucleic acid molecule encoding a mature pheS (alpha) and pheS (beta) polypeptide expressible by the *Streptococcus pneumoniae* 0100993 strain contained in the deposited strain.

A further aspect of the invention there are provided isolated nucleic acid molecules
5 encoding pheS (beta) and/or pheS (alpha), particularly *Streptococcus pneumoniae* pheS (alpha) and/or pheS (beta), including mRNAs, cDNAs, genomic DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

In accordance with another aspect of the invention, there is provided the use of a
10 polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization. Among the particularly preferred embodiments of the invention are naturally occurring allelic variants of pheS (beta) and pheS (alpha) and polypeptides encoded thereby.

Another aspect of the invention there are provided novel polypeptides of *Streptococcus*
15 *pneumoniae* referred to herein as pheS (beta) or pheS (alpha) as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants of either polypeptide, and compositions comprising the same.

Among the particularly preferred embodiments of the invention are variants of pheS (beta) or pheS (alpha) polypeptide encoded by naturally occurring alleles of the pheS (beta) or
20 pheS (alpha) gene, respectively.

In a preferred embodiment of the invention there are provided methods for producing the aforementioned pheS (beta) and pheS (alpha) polypeptides.

In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibacterial agents, including, for example, antibodies.

25 In accordance with certain preferred embodiments of the invention, there are provided products, compositions and methods for assessing pheS (beta) and/or pheS (alpha) expression, treating disease, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid, assaying genetic variation, and administering a pheS
30 (beta) polypeptide or polynucleotide to an organism to raise an immunological response against a bacteria, especially a *Streptococcus pneumoniae* bacteria.

In accordance with certain preferred embodiments of this and other aspects of the invention there are provided polynucleotides that hybridize to pheS (beta) and/or pheS (alpha) polynucleotide sequences, particularly under stringent conditions.

In certain preferred embodiments of the invention there are provided antibodies against pheS (beta) and/or pheS (alpha) polypeptides.

In other embodiments of the invention there are provided methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the invention comprising: contacting a polypeptide or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the polypeptide or polynucleotide to assess the binding to or other interaction with the compound, such binding or interaction being associated with a second component capable of providing a detectable signal in response to the binding or interaction of the polypeptide or polynucleotide with the compound; and determining whether the compound binds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detecting the presence or absence of a signal generated from the binding or interaction of the compound with the polypeptide or polynucleotide.

In accordance with yet another aspect of the invention, there are provided pheS (beta) and/or pheS (alpha) agonists and antagonists, preferably bacteriostatic or bacteriocidal agonists and antagonists.

In a further aspect of the invention there are provided compositions comprising a pheS (beta) polynucleotide or a pheS (beta) polypeptide for administration to a cell or to a multicellular organism.

In a further aspect of the invention there are provided compositions comprising a pheS (alpha) polynucleotide or a pheS (alpha) polypeptide for administration to a cell or to a multicellular organism.

Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.

GLOSSARY

The following definitions are provided to facilitate understanding of certain terms used frequently herein.

"Host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings

of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 5 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity are designed to give the largest match between the

10 sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 (1990). The

15 BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the

20 reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides

25 up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. Analogously, by a

30 polypeptide having an amino acid sequence having at least, for example, 95% identity to a reference amino acid sequence of SEQ ID NO:2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2. In other words, to obtain a polypeptide having an amino acid

sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference
5 sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

"Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in
10 nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

"Polynucleotide(s)" generally refers to any polyribonucleotide or
15 polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotide(s)" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and triple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more
20 typically, double-stranded, or triple-stranded regions, or a mixture of single- and double-stranded regions. In addition, "polynucleotide" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the
25 molecules of a triple-helical region often is an oligonucleotide. As used herein, the term "polynucleotide(s)" also includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotide(s)" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name
30 just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term "polynucleotide(s)" as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including, for

example, simple and complex cells. "Polynucleotide(s)" also embraces short polynucleotides often referred to as oligonucleotide(s).

"Polypeptide(s)" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds. "Polypeptide(s)" refers to both
5 short chains, commonly referred to as peptides, oligopeptides and oligomers and to longer chains generally referred to as proteins, and further includes homo- and hethero-dimers, trimers and tetramers of pheS (beta) and/or pheS (alpha). Polypeptides may contain amino acids other than the 20 gene encoded amino acids. "Polypeptide(s)" include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical
10 modification techniques. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill in the art. It will be appreciated that the same type of modification may be present in the same or varying degree at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Modifications can occur anywhere in a polypeptide,
15 including the peptide backbone, the amino acid side-chains, and the amino or carboxyl termini. Modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation,
20 demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, selenoylation,
25 sulfation, transfer-RNA mediated addition of amino acids to proteins, such as arginylation, and ubiquitination. See, for instance, *PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993) and Wold, F., Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in *POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS*, B. C. Johnson, Ed.,
30 Academic Press, New York (1983); Seifter et al., *Meth. Enzymol.* 182:626-646 (1990) and Rattan et al., *Protein Synthesis: Posttranslational Modifications and Aging*, Ann. N.Y. Acad. Sci. 663: 48-62 (1992). Polypeptides may be branched or cyclic, with or without branching. Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well.

“Variant(s)” as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.

DESCRIPTION OF THE INVENTION

The invention relates to novel pheS (beta) and pheS (alpha) polypeptides and polynucleotides as described in greater detail below. In particular, the invention relates to polypeptides and polynucleotides of a novel pheS (beta) and pheS (alpha) of *Streptococcus pneumoniae*, which is related by amino acid sequence homology to *Bacillus subtilis* phenylalanyl tRNA synthetase beta or alpha sub-unit polypeptide, respectively. The invention relates especially to pheS (beta) comprising the nucleotide and amino acid sequences set out in Table 1 [SEQ ID NO: 1] and Table 1 [SEQ ID NO: 2] respectively, and to the pheS (beta) nucleotide sequences of the DNA in the deposited strain and amino acid sequences encoded thereby. The invention also relates especially to pheS (alpha) comprising the nucleotide and amino acid sequences set out in Table 1 [SEQ ID NO: 5] and Table 1 [SEQ ID NO: 6] respectively, and to the pheS (alpha) nucleotide sequences of the DNA in the deposited strain and amino acid sequences encoded thereby.

TABLE 1

pheS (beta) and pheS (alpha) Polynucleotide and Polypeptide Sequences

5	(A)	Sequences from <i>Streptococcus pneumoniae</i> pheS (beta) polynucleotide sequence [SEQ ID NO:1].
	5'-1	ATGCTTGTAT CTTATAAATG GTTAAAAGAA TTGGTGGACA TTGATGTGCC
	51	ATCACAAGAG TTGGCTGAAA AAATGTCAAC TACAGGGATC GAGGTAGAGG
10	101	GTGTCGAATT ACCAGCTGCT GGTCTCTCAA AAATTGTCGT CGGTGAGGTC
	151	TTGTCTTGCG AAGCTGTGCC AGAGACTCAC CTCCATGTTT GTCAGATTAA
15	201	CGTTGGCGAA GAAGAAGAGC GTCAGATCGT TTGTGGTGCC CCAAATGTGC
	251	GTGCTGGGAT CAAGGTCATG GTGGCTCTTC CAGGAGCTCG TATCGCTGAT
	301	AACTACAAAA TCAAAAAAGG AAAAATCCGT GGTTTGGAGT CACTTGGAAT
20	351	GATCTGTTCA CTTGGTGAAT TGGGAATTTT TGAATCAGTT GTGCCTAAGG
	401	AATTCGCAGA TGGCATCCAA ATCTTGCCCTG AAGATGCCGT GCCAGGTGAG
25	451	GAAGTCTTTT CTTACCTAGA CTTGGATGAT GAAATCATCG AACTTTCCAT
	501	CACACCAAAC CGTGCAGATG CCCTTTCTAT GTGTGGAGTG GCTCACGAAG
	551	TGGCAGCCAT CTATGACAAG GCAGTCAACT TTAAAAAATT TACTCTAACA
30	601	GAAACTAATG AAGCTGCGGC AGATGCCCTT TCTGTCAGCA TTGAGACAGA
	651	CAAGGCGCCT TACTATGCAG CTCGTATCTT GGACAATGTG ACTATCGCAC
35	701	CAAGTCCACA ATGGTTGCAA AACCTTCTCA TGAACGAAGG CATCCGTCCC
	751	ATCAATAACG TTGTAGACGT GACAAACTAC ATCCTGCTCT ACTTTGGTCA
	801	ACCTATGCAT GCTTTTGAAT TGGACACATT TGAAGGGACT GACATCCGTG
40	851	TGCGTGAAGC GCGTGATGGT GAAAAATTAG TGACCCTGGA CGGTGAAGAA

901 CGAGACTTGG CTGAGACAGA CCTCGTGATT ACAGTTGCTG ACAAACCAGT
951 AGCCCTTGCC GGTGTTATGG GTGGTCAGGC TACAGAAATT TCTGAAAAAT
5 1001 CTAGTCGTGT TATCCTTGAA GCTGCTGTTT TTAATGGCAA ATCTATCCGT
1051 AAGACAAGTG GTCGCCTGAA CCTTCGTTCT GAGTCATCTT CTCGCTTTGA
1101 AAAAGGAATT AATGTGGCAA CAGTTAATGA AGCCCTTGAT GCGGCAGCTA
10 1151 GCATGATTGC AGAGCTTGCA GGCGCGACGG TCGTAAGGG TATCGTTTCA
1201 GCGGGTGAGC TTGATACCTC TGATGTGGAA GTTCTTCTCA CCCTTGCTGA
15 1251 TGTTAACCGT GTCCTCGGAA CTGAGCTGTC TTATGCTGAT GTANAAGACG
1301 TCTTCCGTCG TCTTGGCTTT GGTCTTTCTG GAAATGCAGA CAGCTTTACA
1351 GTCAGCGTAC CACGTCGTCG TTGGGATATC ACAATCGAAG CTGATCTCTT
20 1401 TGAAGAAATC GCTCGTATCT ATGGATATGA CCGCTTGCCA ACCAGCCTTC
1451 CAAAAGACGA TGGTACAGCT GGTGAATTGA CTGTGATACA AAAACTCCGC
25 1501 CGTCAAGTTC GTACCATTCG TGAAGGAGCA GGTTTGACAG AAATCATCAC
1551 CTATGCTCTG ACAACTCCTG AAAAAGCAGT TGAGTTCACA GCTCAACCAA
1601 GTAACCTTAC TGAACTCATG TGGCCAATGA CTGTGGATCG TTCAGTCCTC
30 1651 CGTCAAAATA TGATTTTCAGG GATCCTTGTT ACCGTTGCCT ACAACGTGGC
1701 TCGTAAGAAT AAAAAGCTGG CCCTTTATGA GATTGGAAAA GTCTTTGAAC
35 1751 AAACAGGTAA TCCAAAAGAA GAACTTCCAA ATGAGATCAA CAGCTTTGCC
1801 TTTGCTTTGA CAGGCTTGGT TGCTGAAANA GATTTCCAA CAGCAGCAGT
1851 TCCAGTTGAT TTTTTTTATG CTAAGGGAAT CCTTGAAGCC NTATTTACTC
40 1901 GTTTGGGACT CCAAGTAACC TATACAGCAA CATCTGAAAT CGNTAGCCTT
1951 CATCCAGGTC GTACAGCCGT GATTTCACCT GGTGACCAAG TTCTTGGTTT

2001 CCTTGGCCAA GTGCATCCAG TCACTGCCAA GGCTTACGAT ATTCCAGAAA
 2051 CGTATGTAGC TGAGCTTAAC CTTTCAGCCA TCGAAGGGGC GCTCCAACCT
 5 2101 GCTGTTCCAT TTGTGGAAAT CACCAGATTC CCAGCAGTCA GCCGTGACGT
 2151 TGCCTTTCTC CTCAAGGCAG AAGTGA CTCA CCAAGCAGTT GTAGATGCTA
 2201 TCCAAGCTGC CGGCGTGAAA CGTTTGACAG ATATCAGACT CTTTGACGTC
 10 2251 TTCTCAGGTG AAAA ACTGGG ACTTG GTATG AAGTCAATGG CTTATAGCTT
 2301 GACCTTCCAA AATCCAGAAG ACAGCTTAAC GGACGAAGAA GTCGCACGCT -3'

15 (B) pheS (beta) polypeptide sequence deduced from the polynucleotide sequence in this table [SEQ ID NO:2].

NH₂-1 MLVSYKWLKE LVDIDVPSQE LAEKMSTGI EVEGVLPAA GLSKIVVGEV

51 LSCEAVPETH LHVCQINVGE EEERQIVCGA PNV RAGIKVM VALPGARIAD
 20 101 NYKIKKGKIR GLESLGMICS LGELGISDSV VPKEFADGIQ ILPEDAVPGE
 151 EVFSYLDLDD EIIELSITPN RADALSMCGV AHEVAAIYDK AVNFKKFTLT
 25 201 ETNEAAADAL SVSIETDKAP YYAARILDNV TIAPSPQWLQ NLLMNEGIRP
 251 INNVDVTNY ILLYFGQPMH AFDLDTFEGT DIRVREARDG EKLVTLDGEE
 301 RDLAETDLVI TVADKPVALA GVMGGQATEI SEKSSRVILE AAVFNGKSIR
 30 351 KTSGRNLNRS ESSSRFEKGI NVATVNEALD AAASMIAELA GATVRKGIVS
 401 AGELDTS DVE VSSTLADVNR VLGTELSYAD VXDVFRR LGF GLSGNADSFT
 35 451 VSVPRRRWDI TIEADLFEEI ARIYGYDRLP TSLPKDDGTA GELTVIQKLR
 501 RQVRTIAEGA GLTEIITYAL TTPEKAVEFT AQPSNLTELM WPMTVDRSVL
 551 RQNMISGILV TVAYNVARKN KNLALYEIGK VFEQTGNPKE ELPNEINSFA
 40 601 FALTGLVAEX DFQTA AVPVD FFYAKGILEA XFTRLGLQVT YTATSEIXSL
 651 HPGRTAVISL GDQVLGFLGQ VHPVTAKAYD IPETYVAELN LSAIEGALQP

701 AVPFVEITRF PAVSRDVAFL LKAEVTHQAV VDAIQAAGVK RLTDIRLFDV

751 FSGEKLGLGM KSMAYSLTFQ NPEDSLTDEE VAR-COOH

5

(C) pheS (beta) polynucleotide sequence embodiments [SEQ ID NO:1].

X-(R₁)_n-1 ATGCTTGTAT CTTATAAATG GTTAAAAGAA TTGGTGGACA TTGATGTGCC

10 51 ATCACAAGAG TTGGCTGAAA AAATGTCAAC TACAGGGATC GAGGTAGAGG

101 GTGTCGAATT ACCAGCTGCT GGTCTCTCAA AAATTGTCGT CGGTGAGGTC

15 151 TTGTCTTGCG AAGCTGTGCC AGAGACTCAC CTCCATGTTT GTCAGATTAA

201 CGTTGGCGAA GAAGAAGAGC GTCAGATCGT TTGTGGTGCC CCAAATGTGC

251 GTGCTGGGAT CAAGGTCATG GTGGCTCTTC CAGGAGCTCG TATCGCTGAT

20 301 AACTACAAAA TCAAAAAAGG AAAAATCCGT GGTTTGGAGT CACTTGAAT

351 GATCTGTTCA CTTGGTGAAT TGGGAATTTT TGAATCAGTT GTGCCTAAGG

401 AATTCGCAGA TGGCATCCAA ATCTTGCCTG AAGATGCCGT GCCAGGTGAG

25 451 GAAGTCTTTT CTTACCTAGA CTTGGATGAT GAAATCATCG AACTTTCCAT

501 CACACCAAAC CGTGCAGATG CCCTTTCTAT GTGTGGAGTG GCTCACGAAG

30 551 TGGCAGCCAT CTATGACAAG GCAGTCAACT TTAATAAATT TACTCTAACA

601 GAAACTAATG AAGCTGCGGC AGATGCCCTT TCTGTCAGCA TTGAGACAGA

35 651 CAAGGCGCCT TACTATGCAG CTCGTATCTT GGACAATGTG ACTATCGCAC

701 CAAGTCCACA ATGGTTGCAA AACCTTCTCA TGAACGAAGG CATCCGTCCC

751 ATCAATAACG TTGTAGACGT GACAAACTAC ATCCTGCTCT ACTTTGGTCA

40 801 ACCTATGCAT GCTTTTGAAT TGGACACATT TGAAGGGACT GACATCCGTG

851 TGCGTGAAGC GCGTGATGGT GAAAAATTAG TGACCCTGGA CGGTGAAGAA

901 CGAGACTTGG CTGAGACAGA CCTCGTGATT ACAGTTGCTG ACAAACCAGT
951 AGCCCTTGCC GGTGTTATGG GTGGTCAGGC TACAGAAATT TCTGAAAAAT
5 1001 CTAGTCGTGT TATCCTTGAA GCTGCTGTTT TTAATGGCAA ATCTATCCGT
1051 AAGACAAGTG GTCGCCTGAA CCTTCGTTCT GAGTCATCTT CTCGCTTTGA
1101 AAAAGGAATT AATGTGGCAA CAGTTAATGA AGCCCTTGAT GCGGCAGCTA
10 1151 GCATGATTGC AGAGCTTGCA GCGCGACGG TCGGTAAGGG TATCGTTTCA
1201 GCGGGTGAGC TTGATACCTC TGATGTGGAA GTTCTTCAA CCCTTGCTGA
15 1251 TGTTAACCGT GTCCTCGGAA CTGAGCTGTC TTATGCTGAT GTANAAGACG
1301 TCTTCCGTCG TCTTGGCTTT GGTCTTTCTG GAAATGCAGA CAGCTTTACA
1351 GTCAGCGTAC CACGTCGTCG TTGGGATATC ACAATCGAAG CTGATCTCTT
20 1401 TGAAGAAATC GCTCGTATCT ATGGATATGA CCGCTTGCCA ACCAGCCTTC
1451 CAAAAGACGA TGGTACAGCT GGTGAATTGA CTGTGATACA AAAACTCCGC
25 1501 CGTCAAGTTC GTACCATTGC TGAAGGAGCA GGTTTGACAG AAATCATCAC
1551 CTATGCTCTG ACAACTCCTG AAAAAGCAGT TGAGTTCACA GCTCAACCAA
1601 GTAACCTTAC TGAACTCATG TGGCCAATGA CTGTGGATCG TTCAGTCCTC
30 1651 CGTCAAAATA TGATTTTCAGG GATCCTTGTT ACCGTTGCCT ACAACGTGGC
1701 TCGTAAGAAT AAAAAGCTTG CCCTTTATGA GATTGGAAAA GTCTTTGAAC
35 1751 AAACAGGTAA TCCAAAAGAA GAACTTCCAA ATGAGATCAA CAGCTTTGCC
1801 TTTGCTTTGA CAGGCTTGGT TGCTGAAANA GATTTCCAA CAGCAGCAGT
1851 TCCAGTTGAT TTTTTTTATG CTAAGGGAAT CCTTGAAGCC NTATTTACTC
40 1901 GTTTGGGACT CCAAGTAACC TATACAGCAA CATCTGAAAT CGNTAGCCTT
1951 CATCCAGGTC GTACAGCCGT GATTTCATC GGTGACCAAG TTCTTGGTTT

2001 CCTTGGCCAA GTGCATCCAG TCACTGCCAA GGCTTACGAT ATTCCAGAAA
 2051 CGTATGTAGC TGAGCTTAAC CTTTCAGCCA TCGAAGGGGC GCTCCAACCT
 5 2101 GCTGTTCCAT TTGTGGAAAT CACCAGATTC CCAGCAGTCA GCCGTGACGT
 2151 TGCCTTTCTC CTCAAGGCAG AAGTGACTCA CCAAGCAGTT GTAGATGCTA
 2201 TCCAAGCTGC CGGCGTGAAA CGTTTGACAG ATATCAGACT CTTTGACGTC
 10 2251 TTCTCAGGTG AAAAAGTGGG ACTTGGTATG AAGTCAATGG CTTATAGCTT
 2301 GACCTTCCAA AATCCAGAAG ACAGCTTAAC GGACGAAGAA GTCGCACGCT
 - (R₂)_n-Y

15

(D) pheS (beta) polypeptide sequence embodiments [SEQ ID NO:2].

X-(R₁)_n-1 MLVSYKWLKE LVDIDVPSQE LAEKMSTTGI EVEGVLPAA GLSKIVGGEV

51 LSCEAVPETH LHVQCINVGE EEERQIVCGA PNVRAIKVM VALPGARIAD
 20 101 NYKIKKGKIR GLESLGMICS LGELGISDSV VPKEFADGIQ ILPEDAVPGE
 151 EVFSYLDLDD EIIELSITPN RADALSMCGV AHEVAAIYDK AVNFKKFTLT
 25 201 ETNEAAADAL SVSIETDKAP YYAARILDNV TIAPSPQWLQ NLLMNEGIRP
 251 INNVDVTNY ILLYFGQPMH AFDLDTFEGT DIRVREARDG EKLVTLDGEE
 301 RDLAETDLVI TVADKPVALA GVMGGQATEI SEKSSRVILE AAVFNGKSIR
 30 351 KTSGRNLNRS ESSSRFEKGI NVATVNEALD AAASMIAELA GATVRKGIVS
 401 AGELDTS DVE VSSTLADVNR VLGTELSYAD VXDVFRRLLGF GLSGNADSFT
 35 451 VSVPRRRWDI TIEADLFEEI ARIYGYDRLP TSLPKDDGTA GELTVIQKLR
 501 RQVRTIAEGA GLTEIITYAL TTPEKAVEFT AQPSNLTELM WPMTVDRSVL
 551 RQNMISGILV TVAYNVARKN KNLALYEIGK VFEQTGNPKE ELPNEINSFA
 40 601 FALTGLVAEX DFQTAAPVD FFYAKGILEA XFTRLGLQVT YTATSEIXSL
 651 HPGRTAVISL GDQVLGFLGQ VHPVTAKAYD IPETYVAELN LSAIEGALQP

701 AVPFVEITRF PAVSRDVAFL LKAEVTHQAV VDAIQAGVK RLTDIRLFDV

751 FSGEKLGLGM KSMAYSLTFQ NPEDSLTDEE VAR-(R₂)_n-Y

5

(E) Sequences from *Streptococcus pneumoniae* pheS (beta) polynucleotide ORF sequence [SEQ ID NO:3].

5'-1 CGTATCGCTG ATAAC TACAA AATCAAAAAA GGAAAAATCC GTGGTTTGA

10

51 GTCAC TTGGA ATGATCTGTT CACTTGGTGA ATTGGGAATT TCTGACTCAG

101 TTGTGCCTAA GGAATTCGCA GATGGCATCC AAATCTTGCC TGAAGATGCC

15

151 GTGCCAGGTG AGGAAGTCTT TTCTTACCTA GACTTGGATG ATGAAATCAT

201 CGAACTTTCC ATCACACCAA ACCGTGCAGA TGCCCTTTCT ATGTGTGGAG

251 TGGCTCACGA AGTGGCAGCC ATCTATGACA AGGCAGTCAA CTTTAAAAAA

20

301 TTTACTCTAA CAGAACTAA TGAAGCTGCG GCAGATGCCC TTTCTGTCAG

351 CATTGAGACA GACAAGGCGC CTTACTATGC AGCTCGTATC TTGGACAATG

25

401 TGA CTATCGC ACCAAGTCCA CAATGGTTGC AAAACCTTCT CATGAACGAA

451 GCATC-3'

(F) pheS (beta) polypeptide sequence deduced from the polynucleotide ORF sequence in this table [SEQ ID NO:4].

30

NH₂-1 RIADNYKIKK GKIRGLES LG MICSLGELGI SDSVVPKEFA DGIQILPEDA

51 VPGEEVFSYL DLDDEIIELS ITPNRADALS MCGVAHEVAA IYDKAVNFKK

35

101 FTLTETNEAA ADALSVSIET DKAPYYAARI LDNVTIAPSP QWLQNLLMNE

151 A-COOH

(G) pheS (alpha) sequences from *Streptococcus pneumoniae* pheS (alpha)
polynucleotide sequence [SEQ ID NO:5].

5'-1 GGATCCCCCG GGCTGCAGGA ATTAAAAGCG CTCGCGAAG AAACGCTGAC

5 51 TAGCTTGAAG CAGATTACTG CTGGAATGA AAAAGAGATG CAAGATTTCG

101 GTGTCTCTGT CCTTGGTAAA AAGGGTTCGC TTACTGAAAT CCTCAAAGGG

151 ATGAAAGATG TTTCTGCTGA GATGCGTCCA ATCATCGGGA AACACGTCAA

10 201 TGAAGCTCGT GATGTCTTGA CAGCTGCTTT TGAAGAAACA GCTAAGCTCT

251 TGGAAGAAAA GAAAGTCGCG GCTCAACTGG CTAGCGAGAG TATCGATGTG

15 301 ACGCTTCCAG GTCGTCCAGT TGCGACTGGT CACCGTCACG TTTTGACACA

351 AACCAGTGAA GAAATCGAAG ATATCTTCAT CGGTATGGGT TATCAAGTCG

401 TGGATGGTTT TGAAGTGGAG CAAGACTACT ATAAC TTTGA ACGTATGAAC

20 451 CTTC AAAAG ACCACCCAGC TCGTGATATG CAGGATACTT TCTATATCAC

501 TGAAGAAATC TTGCTCCGTA CCCACACGTC TCCAGTTCAG GCACGTGCTA

25 551 TGGATGCCCA TGATTTTCT AAAGGTCCTT TGAAGATAAT CTCGCCAGGG

601 CGTGTCTTCC GTCGCGATAC GGACGATGCG ACCCACAGTC ACCAATTCCA

651 CCAAATCGAA GGCTTG GTAG TTGGGAAAAA TATCTCTATG GCTGATCTTC

30 701 AAGGAACGCT TCAGTTGATT GTCCAAAAAA TGT TTTGGTGA AGAGCGTCAA

751 ATTCGTTTGC GTCCATCTTA CTTC CATTTC ACAGAGCCAT CTGTTGAGGT

35 801 GGATGTTTCT TGCTTCAAAT GTGGTGGAGA AGGCTGTAAC GTATGTAAGA

851 AAACAGGTTG GATCGAAATT ATGGGGGCCG GTATGGTTCA CCCACGTGTC

901 CTTGAAATGA GTGGTATCGA TGCGACTGTA TACTCTGGCT TTGCCTTTGG

40 951 TCTTGGACAA GAGCGTGTAG CTATGCTCCG TTATGGAATC AACGATATCC

1001 GTGGATTCTA CCAAGGAGAT GTCCGCTTCT CAGAACAGTT TAAATAA-3'

(H) pheS (alpha) polypeptide sequence deduced from the polynucleotide sequence in this table [SEQ ID NO:6].

NH₂-1 GSPGLQELKA LREETLTSK QITAGNEKEM QDLRVSVLGK KGSLTEILKG
 5
 51 MKDVSAEMRP IIGKHAVNEAR DVLTAAFEET AKLLEEKKVA AQLASESIDV
 101 TLPGRPVATG HRHVLTQTSE EIEDIFIGMG YQVVDGFEVE QDYNNFERMN
 10 151 LPKDHPARDM QDTFYITEEI LLRTHTSPVQ ARAMDAHDFS KGPLKIISPG
 201 RVFRRDTDDA THSHQFHQIE GLVVGKNISM ADLQGTLLQI VQKMFGEERQ
 251 IRLRPSYFPF TEPSVEVDVS CFKCGGEGCN VCKKTGWIEI MGAGMVHPRV
 15 301 LEMSGIDATV YSGFAFGLGQ ERVAMLR YGI NDIRGFYQGD VRFSEQFK-COOH

(I) pheS (alpha) polynucleotide sequence embodiments [SEQ ID NO:5].

X-(R₁)_n-1 GGATCCCCCG GGCTGCAGGA ATTAAGCG CTTGCGAAG AAACGCTGAC
 20 51 TAGCTTGAAG CAGATTACTG CTGGAAATGA AAAAGAGATG CAAGATTTGC
 101 GTGTCTCTGT CCTTGGTAAA AAGGGTTCGC TTACTGAAAT CCTCAAAGGG
 25 151 ATGAAAGATG TTTCTGCTGA GATGCGTCCA ATCATCGGGA AACACGTCAA
 201 TGAAGCTCGT GATGTCTTGA CAGCTGCTTT TGAAGAAACA GCTAAGCTCT
 251 TGAAGAAAA GAAAGTCGCG GCTCAACTGG CTAGCGAGAG TATCGATGTG
 30 301 ACGCTTCCAG GTCGTCCAGT TCGACTGGT CACCGTCACG TTTTGACACA
 351 AACCAGTGAA GAAATCGAAG ATATCTTCAT CGGTATGGGT TATCAAGTCG
 35 401 TGGATGGTTT TGAAGTGGAG CAAGACTACT ATAACTTTGA ACGTATGAAC
 451 CTTCCAAAAG ACCACCCAGC TCGTGATATG CAGGATACTT TCTATATCAC
 501 TGAAGAAATC TTGCTCCGTA CCCACACGTC TCCAGTTCAG GCACGTGCTA
 40 551 TGGATGCCCA TGATTTTCTT AAAGGTCCTT TGAAGATAAT CTCGCCAGGG

601 CGTGTCTTCC GTCGCGATAC GGACGATGCG ACCCACAGTC ACCAATTCCA
 651 CCAAATCGAA GGCTTGGTAG TTGGGAAAAA TATCTCTATG GCTGATCTTC
 5 701 AAGGAACGCT TCAGTTGATT GTCCAAAAAA TGTTTGGTGA AGAGCGTCAA
 751 ATTCGTTTGC GTCCATCTTA CTTCCCATTC ACAGAGCCAT CTGTTGAGGT
 801 GGATGTTTCT TGCTTCAAAT GTGGTGGAGA AGGCTGTAAC GTATGTAAGA
 10 851 AAACAGGTG GATCGAAATT ATGGGGGCCG GTATGGTTCA CCCACGTGTC
 901 CTTGAAATGA GTGGTATCGA TGCGACTGTA TACTCTGGCT TTGCCTTTGG
 15 951 TCTTGGACAA GAGCGTGTAG CTATGCTCCG TTATGGAATC AACGATATCC
 1001 GTGGATTCTA CCAAGGAGAT GTCCGCTTCT CAGAACAGTT TAAATAA
 - (R₂)_n-Y

20 (J) pheS (alpha) polypeptide sequence embodiments [SEQ ID NO:6].
 X-(R₁)_n-1 GSPGLQELKA LREETLTSLK QITAGNEKEM QDLRVSVL GK KGSLTEILKG
 51 MKDVSAEMRP IIGKHVNEAR DVLTAAFEET AKLLEKKVA AQLASESIDV
 25 101 TLPGRPVATG HRHVLQTSE EIEDIFIGMG YQVVDGFEVE QDYYNFERMN
 151 LPKDHPARDM QDTFYITEEI LLRTHTSPVQ ARAMDAHDFS KGPLKIISPG
 201 RVFRDRTDDA THSHQFHQIE GLVVGKNISM ADLQGTQLI VQKMFGEERQ
 30 251 IRLRPSYFPF TEPSVEVDVS CFKCGGEGCN VCKKTGWIEI MGAGMVHPRV
 301 LEMSGIDATV YSGFAFGLGQ ERVAMLRYGI NDIRGFYQGD VRFSEQFK-
 (R₂)_n-Y

35 (K) Sequences from *Streptococcus pneumoniae* pheS (alpha) polynucleotide ORF
 sequence [SEQ ID NO:7].

5'-1 CAATCCACC AAATCGAAGG CTTGGTAGTT GGGAAAAATA TCTCTATGGC
 40 51 TGATCTTCAA GGAACGCTTC AGTTGATTGT CCAAAAAATG TCTGGTGAAG

101 AGCGTCAAAT TCGTTTGCCT CCATCTTACT TCCCATTAC ACACCCATCT

151 GTTGAGGTGG ATGTTTCTTG CTTCAAATGT GGTGGAGAAG GCTGTAA-3'

5 (L) pheS (alpha) polypeptide sequence deduced from the polynucleotide ORF sequence in this table [SEQ ID NO:8].

NH₂-1 QFHQIEGLVV GKNISMADLQ GTLQLIVQKM SGEERQIRLR PSYFPFTHPS

51 VEVDVSCFKC GGEGC-COOH

10

Deposited materials

A deposit containing a *Streptococcus pneumoniae* 0100993 strain has been deposited with the National Collections of Industrial and Marine Bacteria Ltd. (herein "NCIMB"), 23 St. Machar Drive, Aberdeen AB2 1RY, Scotland on 11 April 1996 and assigned deposit number 40794. The deposit was described as *Streptococcus pneumoniae* 0100993 on deposit. On 17 April 1996 a *Streptococcus pneumoniae* 0100993 DNA library in *E. coli* was similarly deposited with the NCIMB and assigned deposit number 40800. The *Streptococcus pneumoniae* strain deposit is referred to herein as "the deposited strain" or as "the DNA of the deposited strain."

The deposited strain contains both the full length pheS (beta) and pheS (alpha) genes. The sequence of the polynucleotides contained in the deposited strain, as well as the amino acid sequence of the polypeptide encoded thereby, are controlling in the event of any conflict with any description of sequences herein.

The deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. The deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. §112.

A license may be required to make, use or sell the deposited strain, and compounds derived therefrom, and no such license is hereby granted.

Polypeptides

The polypeptides of the invention include the polypeptides of Table 1 [SEQ ID NO:2, 4, 6, 8] (in particular the mature polypeptide) as well as polypeptides and fragments, particularly

those which have the biological activity of pheS (beta) and/or pheS (alpha), and also those which have at least 70% identity to a polypeptide of Table 1 [SEQ ID NOS:2, 4, 6, 8] or the relevant portion, preferably at least 80% identity to a polypeptide of Table 1 [SEQ ID NOS:2, 4, 6, 8], and more preferably at least 90% similarity (more preferably at least 90% identity) to a polypeptide of Table 1 [SEQ ID NOS:2, 4, 6, 8] and still more preferably at least 95% similarity (still more preferably at least 95% identity) to a polypeptide of Table 1 [SEQ ID NOS:2, 4, 6, 8] and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 30 amino acids and more preferably at least 50 amino acids.

The invention also includes polypeptides of the formula set forth in Table 1 (D and J) [SEQ ID NO:2, 6] wherein, at the amino terminus, X is hydrogen, and at the carboxyl terminus, Y is hydrogen or a metal, R₁ and R₂ is any amino acid residue, and n is an integer between 1 and 1000. Any stretch of amino acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.

A fragment is a variant polypeptide having an amino acid sequence that entirely is the same as part but not all of the amino acid sequence of the aforementioned polypeptides. As with pheS (beta) and pheS (alpha) polypeptides fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region, a single larger polypeptide.

Preferred fragments include, for example, truncation polypeptides having a portion of an amino acid sequence of Table 1 [SEQ ID NOS:2, 4, 6, 8], or of variants thereof, such as a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus. Degradation forms of the polypeptides of the invention in a host cell, particularly a *Streptococcus pneumoniae*, are also preferred. Further preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

Also preferred are biologically active fragments which are those fragments that mediate activities of pheS (beta) and/or pheS (alpha), including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those fragments that are antigenic or immunogenic in an animal, especially in a human. Particularly preferred are fragments comprising receptors or domains of enzymes that confer a function essential for

viability of *Streptococcus pneumoniae* or the ability to initiate, or maintain cause disease in an individual, particularly a human.

Variants that are fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these
5 variants may be employed as intermediates for producing the full-length polypeptides of the invention.

In addition to the standard one letter amino acid codes, the term "X" is also used in certain of the polynucleotide embodiments herein (see Table 1). "X" means that any of the twenty naturally occurring amino acids may appear at such a designated position in the
10 polypeptide sequence.

Polynucleotides

Another aspect of the invention relates to isolated polynucleotides that encode the pheS (beta) or pheS (alpha) polypeptide having a deduced amino acid sequence of Table 1 [SEQ ID NOS:2, 4, 6, 8] and polynucleotides closely related thereto and variants thereof.

15 Using the information provided herein, such as a polynucleotide sequence set out in Table 1 [SEQ ID NOS:1, 3, 5, 7], a polynucleotide of the invention encoding pheS (beta) and/or pheS (alpha) polypeptide may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using *Streptococcus pneumoniae* 0100993 cells as starting material, followed by obtaining a full length
20 clone. For example, to obtain a polynucleotide sequence of the invention, such as a sequence given in Table 1 [SEQ ID NOS:1, 3, 5, 7], typically a library of clones of chromosomal DNA of *Streptococcus pneumoniae* 0100993 in *E.coli* or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished
25 using stringent conditions. By sequencing the individual clones thus identified with sequencing primers designed from the original sequence it is then possible to extend the sequence in both directions to determine the full gene sequence. Conveniently, such sequencing is performed using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al.,
30 *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70). Illustrative of the invention, the polynucleotide set out in Table 1 [SEQ ID NO:1] was discovered in a DNA library derived from *Streptococcus pneumoniae* 0100993.

The DNA sequence set out in Table 1 [SEQ ID NOS:1, 5] contains an open reading frame encoding a protein having about the number of amino acid residues set forth in Table 1 [SEQ ID NOS:2, 6 respectively] with a deduced molecular weight that can be calculated using amino acid residue molecular weight values well known in the art. The start codon of the DNA of full length pheS (beta) in Table 1 is nucleotide number 1 and last codon that encodes an amino acid is number 2350, the stop codon being the next codon following this last codon encoding an amino acid. The start codon of the DNA of full length pheS (alpha) in Table 1 is nucleotide number 1 and last codon that encodes an amino acid is number 1044, the stop codon being the next codon following this last codon encoding an amino acid.

pheS (beta) and pheS (alpha) of the invention is structurally related to other proteins of the phenylalanyl tRNA synthetase (alpha and beta sub-unit) family, as shown by the results of sequencing the DNA encoding pheS (beta) and pheS (alpha) of the deposited strain. The pheS (beta) protein exhibits greatest homology to *Bacillus subtilis* phenylalanyl tRNA synthetase beta sub-unit protein among known proteins. pheS (beta) of Table 1 [SEQ ID NO:2] has about 47% identity over its entire length and about 64% similarity over its entire length with the amino acid sequence of *Bacillus subtilis* phenylalanyl tRNA synthetase beta sub-unit polypeptide. The pheS (alpha) protein exhibits greatest homology to *Bacillus subtilis* phenylalanyl tRNA synthetase (alpha sub-unit) protein among known proteins. pheS (alpha) of Table 1 [SEQ ID NO:6] has about 62% identity over its entire length and about 75% similarity over its entire length with the amino acid sequence of *Bacillus subtilis* phenylalanyl tRNA synthetase (alpha sub-unit) polypeptide.

The invention provides a polynucleotide sequence identical over its entire length to each full length coding sequence in Table 1 [SEQ ID NO:1, 5]. Also provided by the invention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a fragment in reading frame with other coding sequence, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence. The polynucleotide may also contain non-coding sequences, including for example, but not limited to non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences, termination signals, ribosome binding sites, sequences that stabilize mRNA, introns, polyadenylation signals, and additional coding sequence which encode additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, *Proc. Natl. Acad. Sci., USA* 86: 821-824 (1989), or an HA tag (Wilson *et al.*, *Cell* 37: 767 (1984).

Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.

A preferred embodiment of the invention is the polynucleotide of comprising nucleotide 1 to 2034 set forth in SEQ ID NO:1 of Table 1 which encodes the pheS (beta) polypeptide. A
5 further preferred embodiment of the invention is the polynucleotide of comprising nucleotide 1 to 915 set forth in SEQ ID NO:5 of Table 1 which encodes the pheS (alpha) polypeptide.

The invention also includes polynucleotides of the formula set forth in Table 1 (C and D)[SEQ ID NO:1 and 5 respectively] wherein, at the 5' end of the molecule, X is hydrogen, and at the 3' end of the molecule, Y is hydrogen or a metal, R₁ and R₂ is any nucleic acid residue, and
10 n is an integer between 1 and 1000. Any stretch of nucleic acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.

The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a
15 bacterial polypeptide and more particularly a polypeptide of the *Streptococcus pneumoniae* pheS (beta) or pheS (alpha) comprising the amino acid sequence set out in Table 1 [SEQ ID NO:2 and 6 respectively]. The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, interrupted by integrated phage or an insertion sequence or editing) together with additional regions, that also may contain
20 coding and/or non-coding sequences.

In addition to the standard A, G, C, T/U representations for nucleic acid bases, the term "N" is also used in polynucleotide sequences herein. "N" means that any of the four DNA or RNA bases may appear at such a designated position in the DNA or RNA sequence, except that N cannot be a base that when taken in combination with adjacent
25 nucleotide positions, when read in the correct reading frame, would have the effect of generating a premature termination codon in such reading frame.

The invention further relates to variants of the polynucleotides described herein that encode for variants of the polypeptide having a deduced amino acid sequence of Table 1 [SEQ ID NO:2, 6]. Variants that are fragments of the polynucleotides of the invention may be used to
30 synthesize full-length polynucleotides of the invention.

Further particularly preferred embodiments are polynucleotides encoding pheS (beta) and/or pheS (alpha) variants, that have the amino acid sequence of pheS (beta) or pheS (alpha) polypeptide of Table 1 [SEQ ID NO:2 and 6 respectively] in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, deleted or added, in any combination.

Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of pheS (beta) or pheS (alpha) .

Further preferred embodiments of the invention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encoding pheS (beta) and/or pheS (alpha) polypeptide having an amino acid sequence set out in Table 1 [SEQ ID NOS:2, 4, 6, 8], and polynucleotides that are complementary to such polynucleotides. Alternatively, most highly preferred are polynucleotides that comprise a region that is at least 80% identical over its entire length to a polynucleotide encoding pheS (beta) and/or pheS (alpha) polypeptide of the deposited strain and polynucleotides complementary thereto. In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

Preferred embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by the DNA of Table 1 [SEQ ID NO:1, 5].

The invention further relates to polynucleotides that hybridize to the herein above-described sequences. In this regard, the invention especially relates to polynucleotides that hybridize under stringent conditions to the herein above-described polynucleotides. As herein used, the terms "stringent conditions" and "stringent hybridization conditions" mean hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences. An example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1x SSC at about 65°C. Hybridization and wash conditions are well known and exemplified in Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein.

The invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:5 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:5 respectively or a

fragment thereof; and isolating said DNA sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and primers described elsewhere herein.

As discussed additionally herein regarding polynucleotide assays of the invention, for instance, polynucleotides of the invention as discussed above, may be used as a hybridization
5 probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding pheS (beta) and/or pheS (alpha) and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the pheS (beta) and/or pheS (alpha) gene. Such probes generally will comprise at least 15 bases. Preferably, such probes will have at least 30 bases and may have at least 50 bases. Particularly preferred probes will have at least 30 bases
10 and will have 50 bases or less.

For example, the coding region of the pheS (beta) and/or pheS (alpha) gene may be isolated by screening using the DNA sequence provided in SEQ ID NO: 1 or 5 to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to
15 determine which members of the library the probe hybridizes to.

The polynucleotides and polypeptides of the invention may be employed, for example, as research reagents and materials for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herein relating to polynucleotide assays.

Polynucleotides of the invention that are oligonucleotides derived from the
20 sequences of SEQ ID NOS:1 and/or 2 and/or 5 and/or 6 may be used in the processes herein as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed in bacteria in infected tissue. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained.

25 The invention also provides polynucleotides that may encode a polypeptide that is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate
30 manipulation of a protein for assay or production, among other things. As generally is the case *in vivo*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

A precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed such

inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein
5 having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

Vectors, host cells, expression

10 The invention also relates to vectors that comprise a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the invention.

15 For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis et al., *BASIC METHODS IN MOLECULAR BIOLOGY*, (1986) and Sambrook et al., *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed.,
20 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection.

Representative examples of appropriate hosts include bacterial cells, such as
25 streptococci, staphylococci, enterococci *E. coli*, streptomyces and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used to produce the polypeptides of the
30 invention. Such vectors include, among others, chromosomal, episomal and virus-derived vectors, *e.g.*, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof,

such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression system constructs may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard. The appropriate DNA sequence may be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, *MOLECULAR CLONING, A LABORATORY MANUAL*, (*supra*).

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.

Polypeptides of the invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding protein may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

Diagnostic Assays

This invention is also related to the use of the pheS (beta) and/or pheS (alpha) polynucleotides of the invention for use as diagnostic reagents. Detection of pheS (beta) and/or pheS (alpha) in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of a disease. Eukaryotes (herein also "individual(s)"), particularly mammals, and especially humans, infected with an organism comprising the pheS (beta) and/or pheS (alpha) gene may be detected at the nucleic acid level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification technique prior to analysis. RNA or cDNA may also be used in the same ways. Using amplification, characterization of the species and strain of prokaryote present in an individual, may be made by an analysis of the genotype of the prokaryote gene. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the genotype of a reference sequence.

Point mutations can be identified by hybridizing amplified DNA to labeled pheS (beta) and/or pheS (alpha) polynucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers et al., *Science*, 230: 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and S1 protection or a chemical cleavage method. See, e.g., Cotton et al., *Proc. Natl. Acad. Sci., USA*, 85: 4397-4401 (1985).

Cells carrying mutations or polymorphisms in the gene of the invention may also be detected at the DNA level by a variety of techniques, to allow for serotyping, for example. For example, RT-PCR can be used to detect mutations. It is particularly preferred to use RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan. RNA or cDNA may also be used for the same purpose, PCR or RT-PCR. As an example, PCR primers complementary to a nucleic acid encoding pheS (beta) and/or pheS (alpha) can be used to identify and analyze mutations. The invention further provides these primers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end. These primers may be used for, among other things, amplifying pheS (beta) and/or pheS (alpha) DNA isolated from a sample derived from an individual. The primers may be used to amplify the gene isolated from an infected individual such that the gene may then be subject to various techniques for elucidation of the DNA sequence. In this way, mutations in the DNA sequence may be detected and used to diagnose infection and to serotype and/or classify the infectious agent.

The invention further provides a process for diagnosing disease, preferably bacterial infections, more preferably infections by *Streptococcus pneumoniae*, and most preferably otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid, comprising determining from a sample derived from an individual a increased level of expression of polynucleotide comprising a sequence of Table 1 [SEQ ID NO: 1 and/or 5]. Increased or decreased expression of pheS (beta) and/or pheS (alpha) polynucleotide can be measured using any one of the methods well known in the art for the quantitation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.

In addition, a diagnostic assay in accordance with the invention for detecting over-expression of pheS (beta) and/or pheS (alpha) protein compared to normal control tissue samples

may be used to detect the presence of an infection, for example. Assay techniques that can be used to determine levels of a pheS (beta) and/or pheS (alpha) protein, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

5 Antibodies

The polypeptides of the invention or variants thereof, or cells expressing them can be used as an immunogen to produce antibodies immunospecific for such polypeptides. "Antibodies" as used herein includes monoclonal and polyclonal antibodies, chimeric, single chain, simianized antibodies and humanized antibodies, as well as Fab fragments, including the
10 products of an Fab immunoglobulin expression library.

Antibodies generated against the polypeptides of the invention can be obtained by administering the polypeptides or epitope-bearing fragments, analogues or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique known in the art that provides antibodies produced by continuous cell line cultures can
15 be used. Examples include various techniques, such as those in Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975); Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, pg. 77-96 in *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc. (1985).

Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to polypeptides of this invention. Also,
20 transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies.

Alternatively phage display technology may be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v-
genes of lymphocytes from humans screened for possessing anti-pheS (beta), anti-pheS
25 (alpha) or from naive libraries (McCafferty, J. *et al.*, (1990), *Nature* 348, 552-554; Marks, J. *et al.*, (1992) *Biotechnology* 10, 779-783). The affinity of these antibodies can also be improved by chain shuffling (Clackson, T. *et al.*, (1991) *Nature* 352, 624-628).

If two antigen binding domains are present each domain may be directed against a different epitope - termed 'bispecific' antibodies.

30 The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptides to purify the polypeptides by affinity chromatography.

Thus, among others, antibodies against pheS (beta)- and/or pheS (alpha)-polypeptide may be employed to treat infections, particularly bacterial infections and especially otitis media,

conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid.

Polypeptide variants include antigenically, epitopically or immunologically equivalent variants that form a particular aspect of this invention. The term "antigenically equivalent derivative" as used herein encompasses a polypeptide or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protein or polypeptide according to the invention, interfere with the immediate physical interaction between pathogen and mammalian host. The term "immunologically equivalent derivative" as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical interaction between pathogen and mammalian host.

The polypeptide, such as an antigenically or immunologically equivalent derivative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken. The fusion protein may provide stability to the polypeptide. The antigen may be associated, for example by conjugation, with an immunogenic carrier protein for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH). Alternatively a multiple antigenic peptide comprising multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier.

Preferably, the antibody or variant thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized"; where the complementarity determining region(s) of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody, for example as described in Jones, P. et al. (1986), Nature 321, 522-525 or Tempest et al., (1991) Biotechnology 9, 266-273.

The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al., Hum Mol Genet 1992, 1:363, Manthorpe et al., Hum. Gene Ther. 1993:4, 419), delivery of DNA complexed with specific protein carriers (Wu et al., J Biol Chem. 1989: 264,16985), coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef, PNAS, 1986:83,9551), encapsulation of DNA in various forms of liposomes (Kaneda et al., Science 1989:243,375), particle bombardment (Tang et al., Nature 1992, 356:152, Eisenbraun et al., DNA Cell Biol 1993, 12:791) and *in vivo* infection using cloned retroviral vectors (Seeger et al., PNAS 1984:81,5849).

Antagonists and agonists - assays and molecules

Polypeptides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, *e.g.*, Coligan *et al.*, *Current Protocols in Immunology* 1(2): Chapter 5 (1991).

The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of pheS (beta) and/or pheS (alpha) polypeptides, including dimers of pheS (beta) and pheS (alpha), or polynucleotides, particularly those compounds that are bacteriostatic and/or bacteriocidal. The method of screening may involve high-throughput techniques. For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, comprising pheS (beta) and/or pheS (alpha) polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that may be a pheS (beta) and/or pheS (alpha) agonist or antagonist. The ability of the candidate molecule to agonize or antagonize the pheS (beta) and/or pheS (alpha) polypeptide is reflected in decreased binding of the labeled ligand or decreased production of product from such substrate. Molecules that bind gratuitously, *i.e.*, without inducing the effects of pheS (beta) and/or pheS (alpha) polypeptide are most likely to be good antagonists. Molecules that bind well and increase the rate of product production from substrate are agonists. Detection of the rate or level of production of product from substrate may be enhanced by using a reporter system. Reporter systems that may be useful in this regard include but are not limited to colorimetric labeled substrate converted into product, a reporter gene that is responsive to changes in pheS (beta) and/or pheS (alpha) polynucleotide or polypeptide activity, and binding assays known in the art.

Another example of an assay for pheS (beta) and/or pheS (alpha) antagonists is a competitive assay that combines pheS (beta) and/or pheS (alpha) and a potential antagonist with pheS (beta)- and/or pheS (alpha)-binding molecules, recombinant pheS (beta) and/or pheS (alpha) binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. pheS (beta) and pheS (alpha) can be labeled, such as by radioactivity or a colorimetric compound, such that the number of pheS (beta) and/or pheS (alpha) molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide or polypeptide of the invention and thereby inhibit or extinguish its activity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding
5 molecule, such as a binding molecule, without inducing pheS (beta)- and/or pheS (alpha)-induced activities, thereby preventing the action of pheS (beta) and/or pheS (alpha) by excluding pheS (beta) and/or pheS (alpha) from binding.

Potential antagonists include a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that
10 normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules (see Okano, *J. Neurochem.* 56: 560 (1991); *OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION*, CRC Press, Boca Raton, FL (1988), for a description of these molecules). Preferred potential
15 antagonists include compounds related to and variants of pheS (beta) and/or pheS (alpha) .

Each of the DNA sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein, upon expression, can be used as a target for the screening of antibacterial drugs. Additionally, the DNA sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other
20 translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

The invention also provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection. In particular the molecules of the
25 invention may be used: in the prevention of adhesion of bacteria, in particular gram positive bacteria, to mammalian extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block pheS (beta) and/or pheS (alpha) protein-mediated mammalian cell invasion by, for example, initiating phosphorylation of mammalian tyrosine kinases (Rosenshine *et al.*, *Infect. Immun.* 60:2211 (1992); to block
30 bacterial adhesion between mammalian extracellular matrix proteins and bacterial pheS (beta) and/or pheS (alpha) proteins that mediate tissue damage and; to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.

The antagonists and agonists of the invention may be employed, for instance, to inhibit and treat otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid.

5 Vaccines

Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal which comprises inoculating the individual with pheS (beta) and/or pheS (alpha), or a fragment or variant thereof, such as pheS (alpha)- pheS (beta) fusions, adequate to produce antibody and/ or T cell immune
10 response to protect said individual from infection, particularly bacterial infection and most particularly *Streptococcus pneumoniae* infection. Also provided are methods whereby such immunological response slows bacterial replication. Yet another aspect of the invention relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector to direct expression of pheS (beta) and/or
15 pheS (alpha), or a fragment, fusion or a variant thereof, for expressing pheS (beta) and/or pheS (alpha), or a fragment, fusion or a variant thereof *in vivo* in order to induce an immunological response, such as, to produce antibody and/ or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or
20 not. One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid.

A further aspect of the invention relates to an immunological composition which, when introduced into an individual capable or having induced within it an immunological
25 response, induces an immunological response in such individual to a pheS (beta) and/or pheS (alpha) or protein coded from either, wherein the composition comprises a recombinant pheS (beta) and/or pheS (alpha) or protein coded from either comprising DNA which codes for and expresses an antigen of said pheS (beta) and/or pheS (alpha) or protein coded from either. The immunological response may be used therapeutically or prophylactically and
30 may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells.

A pheS (beta) or pheS (alpha) polypeptide or a fragment of either or fused fragments from both may be fused with co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have

immunogenic and protective properties. Thus fused recombinant protein, preferably further comprises an antigenic co-protein, such as lipoprotein D from *Hemophilus influenzae*, Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubilize the protein and facilitate production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system. The co-protein may be attached to either the amino or carboxy terminus of the first protein.

Provided by this invention are compositions, particularly vaccine compositions, and methods comprising the polypeptides or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y. *et al.* Science 273: 352 (1996).

Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof which have been shown to encode non-variable regions of bacterial cell surface proteins in DNA constructs used in such genetic immunization experiments in animal models of infection with *Streptococcus pneumoniae* will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly *Streptococcus pneumoniae* infection, in mammals, particularly humans.

The polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue. Examples of tissue damage include wounds in skin or connective tissue caused, e.g., by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagina.

The invention also includes a vaccine formulation which comprises an immunogenic recombinant protein of the invention together with a suitable carrier. Since the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the bodily fluid, preferably the

blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier
5 immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

While the invention has been described with reference to certain pheS (beta) and
10 pheS (alpha) protein, it is to be understood that this covers fragments of the naturally occurring protein and similar proteins with additions, deletions or substitutions which do not substantially affect the immunogenic properties of the recombinant protein.

Compositions, kits and administration

The invention also relates to compositions comprising the polynucleotide or the
15 polypeptides discussed above or their agonists or antagonists. The polypeptides of the invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a polypeptide of the invention and a pharmaceutically acceptable carrier or excipient. Such
20 carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration. The invention further relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

25 Polypeptides and other compounds of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.

30 In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

Alternatively the composition may be formulated for topical application

for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also
5 contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.

For administration to mammals, and particularly humans, it is expected that the
10 daily dosage level of the active agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such
15 are within the scope of this invention.

In-dwelling devices include surgical implants, prosthetic devices and catheters, i.e., devices that are introduced to the body of an individual and remain in position for an extended time. Such devices include, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospinal fluid shunts, urinary catheters,
20 continuous ambulatory peritoneal dialysis (CAPD) catheters.

The composition of the invention may be administered by injection to achieve a systemic effect against relevant bacteria shortly before insertion of an in-dwelling device. Treatment may be continued after surgery during the in-body time of the device. In addition, the composition could also be used to broaden perioperative cover for any surgical
25 technique to prevent bacterial wound infections, especially *Streptococcus pneumoniae* wound infections.

Many orthopaedic surgeons consider that humans with prosthetic joints should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia. Late deep infection is a serious complication sometimes leading to loss of the
30 prosthetic joint and is accompanied by significant morbidity and mortality. It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics in this situation.

In addition to the therapy described above, the compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix

proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis.

Alternatively, the composition of the invention may be used to bathe an indwelling device immediately before insertion. The active agent will preferably be present at a concentration of 1µg/ml to 10mg/ml for bathing of wounds or indwelling devices.

A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.5-5 microgram/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals.

Each reference disclosed herein is incorporated by reference herein in its entirety. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety.

15 EXAMPLES

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples are illustrative, but do not limit the invention.

Example 1 Strain selection, Library Production and Sequencing

20 The polynucleotides having the DNA sequence given in SEQ ID NO:1 and 5 were obtained from a library of clones of chromosomal DNA of *Streptococcus pneumoniae* in *E. coli*. The sequencing data from two or more clones containing overlapping *Streptococcus pneumoniae* DNAs was used to construct the contiguous DNA sequence in SEQ ID NO:1 and 5. Libraries may be prepared by routine methods, for example:

25 Methods 1 and 2 below.

Total cellular DNA is isolated from *Streptococcus pneumoniae* 0100993 according to standard procedures and size-fractionated by either of two methods.

Method 1

30 Total cellular DNA is mechanically sheared by passage through a needle in order to size-fractionate according to standard procedures. DNA fragments of up to 11kbp in size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added. Fragments are ligated into the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and *E.coli* infected with the packaged library. The library is amplified by standard procedures.

Method 2

Total cellular DNA is partially hydrolyzed with a one or a combination of restriction enzymes appropriate to generate a series of fragments for cloning into library vectors (e.g., *RsaI*, *Pall*, *AluI*, *BshI235I*), and such fragments are size-fractionated according to standard procedures. *EcoRI* linkers are ligated to the DNA and the fragments then ligated into the vector *Lambda ZapII* that have been cut with *EcoRI*, the library packaged by standard procedures, and *E.coli* infected with the packaged library. The library is amplified by standard procedures.

Example 2 pheS (beta) and pheS (alpha) Characterization

The enzyme mediated incorporation of radiolabelled amino acid into tRNA may be measured by the aminoacylation method which measures amino acid-tRNA as trichloroacetic acid-precipitable radioactivity from radiolabelled amino acid in the presence of tRNA and ATP (Hughes J, Mellows G and Soughton S, 1980, FEBS Letters, 122:322-324). Thus inhibitors of phenylalanyl tRNA synthetase heterodimer can be detected by a reduction in the trichloroacetic acid precipitable radioactivity relative to the control. Alternatively the tRNA synthetase catalysed partial *PPi*/ATP exchange reaction which measures the formation of radiolabelled ATP from *PPi* can be used to detect phenylalanyl tRNA synthetase heterodimer inhibitors (Calender R & Berg P, 1966, Biochemistry, 5, 1681-1690).

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Lawlor, Elizabeth
- (ii) TITLE OF THE INVENTION: Novel Compounds
- (iii) NUMBER OF SEQUENCES: 8
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: SmithKline Beecham Corporation
 - (B) STREET: 709 Swedeland Road
 - (C) CITY: King of Prussia
 - (D) STATE: PA
 - (E) COUNTRY: USA
 - (F) ZIP: 19406-0939
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE: 18-APR-1997
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 9607993.4
 - (B) FILING DATE: 18-APR-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Gimmi, Edward R
 - (B) REGISTRATION NUMBER: 38,891
 - (C) REFERENCE/DOCKET NUMBER: P31457-6
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 610-270-4478
 - (B) TELEFAX: 610-270-5090
 - (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2350 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGCTTGTAT	CTTATAAATG	GTTAAAAGAA	TTGGTGGACA	TTGATGTGCC	ATCACAAGAG	60
TTGGCTGAAA	AAATGTCAAC	TACAGGGATC	GAGGTAGAGG	GTGTCGAATT	ACCAGCTGCT	120
GGTCTCTCAA	AAATTGTCGT	CGGTGAGGTC	TTGTCTTGCG	AAGCTGTGCC	AGAGACTCAC	180
CTCCATGTTT	GTCAGATTAA	CGTTGGCGAA	GAAGAAGAGC	GTCAGATCGT	TTGTGGTGCC	240
CCAAATGTGC	GTGCTGGGAT	CAAGGTCATG	GTGGCTCTTC	CAGGAGCTCG	TATCGCTGAT	300
AACTACAAAA	TCAAAAAAGG	AAAAATCCGT	GGTTTGGAGT	CACTTGGAAT	GATCTGTTCA	360
CTTGGTGAAT	TGGGAATTTT	TGACTCAGTT	GTGCCTAAGG	AATTCGCAGA	TGGCATCCAA	420
ATCTTGCCCTG	AAGATGCCGT	GCCAGGTGAG	GAAGTCTTTT	CTTACCTAGA	CTTGATGAT	480
GAAATCATCG	AACTTTCCAT	CACACCAAAC	CGTGCAGATG	CCCTTTCTAT	GTGTGGAGTG	540
GCTCACGAAG	TGGCAGCCAT	CTATGACAAG	GCAGTCAACT	TTAAAAAATT	TACTCTAACA	600
GAAACTAATG	AAGCTGCGGC	AGATGCCCTT	TCTGTCAGCA	TTGAGACAGA	CAAGGCGCCT	660
TACTATGCAG	CTCGTATCTT	GGACAATGTG	ACTATCGCAC	CAAGTCCACA	ATGTTTGCAA	720
AACCTTCTCA	TGAACGAAGG	CATCCGTCCC	ATCAATAACG	TTGTAGACGT	GACAAACTAC	780
ATCCTGCTCT	ACTTTGGTCA	ACCTATGCAT	GCTTTTGGACT	TGGACACATT	TGAAGGGACT	840
GACATCCGTG	TGCGTGAAGC	GCGTGATGGT	GAAAAATTAG	TGACCCTGGA	CGGTGAAGAA	900
CGAGACTTGG	CTGAGACAGA	CCTCGTGATT	ACAGTTGCTG	ACAAACCAGT	AGCCCTTGCC	960
GGTGTTATGG	GTGGTCAGGC	TACAGAAATT	TCTGAAAAAT	CTAGTCGTGT	TATCCTTGAA	1020
GCTGCTGTTT	TTAATGGCAA	ATCTATCCGT	AAGACAAGTG	GTGCGCTGAA	CCTTCGTCTT	1080
GAGTCATCTT	CTCGCTTTGA	AAAAGGAATT	AATGTGGCAA	CAGTTAATGA	AGCCCTTGAT	1140
GCGGCAGCTA	GCATGATTGC	AGAGCTTGCA	GGCGCGACGG	TGCGTAAGGG	TATCGTTTCA	1200
GCGGGTGAGC	TTGATACCTC	TGATGTGGAA	GTTTCTTCAA	CCCTTGCTGA	TGTTAACCGT	1260
GTCTTCGGAA	CTGAGCTGTC	TTATGCTGAT	GTANAAGACG	TCTTCCGTCG	TCTTGGCTTT	1320
GGTCTTTCTG	GAAATGCAGA	CAGCTTTACA	GTCAGCGTAC	CACGTCGTCG	TTGGGATATC	1380
ACAATCGAAG	CTGATCTCTT	TGAAGAAATC	GCTCGTATCT	ATGGATATGA	CCGCTTGCCA	1440
ACCAGCCTTC	CAAAAGACGA	TGGTACAGCT	GGTGAATTGA	CTGTGATACA	AAAACCTCCG	1500
CGTCAAGTTC	GTACCATTGC	TGAAGGAGCA	GGTTTGACAG	AAATCATCAC	CTATGCTCTG	1560
ACAACCTCCTG	AAAAAGCAGT	TGAGTTTACA	GCTCAACCAA	GTAACCTTAC	TGAACTCATG	1620
TGGCCAATGA	CTGTGGATCG	TTCAGTCCTC	CGTCAAAATA	TGATTTTACG	GATCCTTGTT	1680
ACCGTTGCCCT	ACAACGTGGC	TCGTAAGAAT	AAAAACTTGG	CCCTTTATGA	GATTGGAAAA	1740
GTCTTTGAAC	AAACAGGTAA	TCCAAAAGAA	GAACCTTCAA	ATGAGATCAA	CAGCTTTGCC	1800
TTTGCTTTGA	CAGGCTTGGT	TGCTGAAANA	GATTTCCAAA	CAGCAGCAGT	TCCAGTTGAT	1860
TTTTTTTATG	CTAAGGGAAT	CCTTGAAGCC	NTATTTACTC	GTTTGGGACT	CCAAGTAACC	1920

```

TATACAGCAA CATCTGAAAT CGNTAGCCTT CATCCAGGTC GTACAGCCGT GATTTCACTC 1980
GGTGACCAAG TTCTTGGTTT CCTTGGCCAA GTGCATCCAG TCACTGCCAA GGCTTACGAT 2040
ATTCCAGAAA CGTATGTAGC TGAGCTTAAC CTTTCAGCCA TCGAAGGGGC GCTCCAACCT 2100
GCTGTTCCAT TTGTGGAAAT CACCAGATTC CCAGCAGTCA GCCGTGACGT TGCCTTTCTC 2160
CTCAAGGCAG AAGTGACTCA CCAAGCAGTT GTAGATGCTA TCCAAGCTGC CGGCGTGAAA 2220
CGTTTGACAG ATATCAGACT CTTTGACGTC TTCTCAGGTG AAAAACTGGG ACTTGGTATG 2280
AAGTCAATGG CTTATAGCTT GACCTTCCAA AATCCAGAAG ACAGCTTAAC GGACGAAGAA 2340
GTCGCACGCT 2350

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 783 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Leu Val Ser Tyr Lys Trp Leu Lys Glu Leu Val Asp Ile Asp Val
1           5           10           15
Pro Ser Gln Glu Leu Ala Glu Lys Met Ser Thr Thr Gly Ile Glu Val
20           25           30
Glu Gly Val Glu Leu Pro Ala Ala Gly Leu Ser Lys Ile Val Val Gly
35           40           45
Glu Val Leu Ser Cys Glu Ala Val Pro Glu Thr His Leu His Val Cys
50           55           60
Gln Ile Asn Val Gly Glu Glu Glu Glu Arg Gln Ile Val Cys Gly Ala
65           70           75           80
Pro Asn Val Arg Ala Gly Ile Lys Val Met Val Ala Leu Pro Gly Ala
85           90           95
Arg Ile Ala Asp Asn Tyr Lys Ile Lys Lys Gly Lys Ile Arg Gly Leu
100          105          110
Glu Ser Leu Gly Met Ile Cys Ser Leu Gly Glu Leu Gly Ile Ser Asp
115          120          125
Ser Val Val Pro Lys Glu Phe Ala Asp Gly Ile Gln Ile Leu Pro Glu
130          135          140
Asp Ala Val Pro Gly Glu Glu Val Phe Ser Tyr Leu Asp Leu Asp Asp
145          150          155          160
Glu Ile Ile Glu Leu Ser Ile Thr Pro Asn Arg Ala Asp Ala Leu Ser
165          170          175

```

Met Cys Gly Val Ala His Glu Val Ala Ala Ile Tyr Asp Lys Ala Val
 180 185 190
 Asn Phe Lys Lys Phe Thr Leu Thr Glu Thr Asn Glu Ala Ala Ala Asp
 195 200 205
 Ala Leu Ser Val Ser Ile Glu Thr Asp Lys Ala Pro Tyr Tyr Ala Ala
 210 215 220
 Arg Ile Leu Asp Asn Val Thr Ile Ala Pro Ser Pro Gln Trp Leu Gln
 225 230 235 240
 Asn Leu Leu Met Asn Glu Gly Ile Arg Pro Ile Asn Asn Val Val Asp
 245 250 255
 Val Thr Asn Tyr Ile Leu Leu Tyr Phe Gly Gln Pro Met His Ala Phe
 260 265 270
 Asp Leu Asp Thr Phe Glu Gly Thr Asp Ile Arg Val Arg Glu Ala Arg
 275 280 285
 Asp Gly Glu Lys Leu Val Thr Leu Asp Gly Glu Glu Arg Asp Leu Ala
 290 295 300
 Glu Thr Asp Leu Val Ile Thr Val Ala Asp Lys Pro Val Ala Leu Ala
 305 310 315 320
 Gly Val Met Gly Gly Gln Ala Thr Glu Ile Ser Glu Lys Ser Ser Arg
 325 330 335
 Val Ile Leu Glu Ala Ala Val Phe Asn Gly Lys Ser Ile Arg Lys Thr
 340 345 350
 Ser Gly Arg Leu Asn Leu Arg Ser Glu Ser Ser Ser Arg Phe Glu Lys
 355 360 365
 Gly Ile Asn Val Ala Thr Val Asn Glu Ala Leu Asp Ala Ala Ala Ser
 370 375 380
 Met Ile Ala Glu Leu Ala Gly Ala Thr Val Arg Lys Gly Ile Val Ser
 385 390 395 400
 Ala Gly Glu Leu Asp Thr Ser Asp Val Glu Val Ser Ser Thr Leu Ala
 405 410 415
 Asp Val Asn Arg Val Leu Gly Thr Glu Leu Ser Tyr Ala Asp Val Xaa
 420 425 430
 Asp_Val Phe Arg Arg Leu Gly Phe Gly Leu Ser Gly Asn Ala Asp Ser
 435 440 445
 Phe Thr Val Ser Val Pro Arg Arg Arg Trp Asp Ile Thr Ile Glu Ala
 450 455 460
 Asp Leu Phe Glu Glu Ile Ala Arg Ile Tyr Gly Tyr Asp Arg Leu Pro
 465 470 475 480
 Thr Ser Leu Pro Lys Asp Asp Gly Thr Ala Gly Glu Leu Thr Val Ile
 485 490 495
 Gln Lys Leu Arg Arg Gln Val Arg Thr Ile Ala Glu Gly Ala Gly Leu
 500 505 510
 Thr Glu Ile Ile Thr Tyr Ala Leu Thr Thr Pro Glu Lys Ala Val Glu
 515 520 525

Phe	Thr	Ala	Gln	Pro	Ser	Asn	Leu	Thr	Glu	Leu	Met	Trp	Pro	Met	Thr	
530					535					540						
Val	Asp	Arg	Ser	Val	Leu	Arg	Gln	Asn	Met	Ile	Ser	Gly	Ile	Leu	Val	
545					550					555						560
Thr	Val	Ala	Tyr	Asn	Val	Ala	Arg	Lys	Asn	Lys	Asn	Leu	Ala	Leu	Tyr	
565					570					575						
Glu	Ile	Gly	Lys	Val	Phe	Glu	Gln	Thr	Gly	Asn	Pro	Lys	Glu	Glu	Leu	
580					585					590						
Pro	Asn	Glu	Ile	Asn	Ser	Phe	Ala	Phe	Ala	Leu	Thr	Gly	Leu	Val	Ala	
595					600					605						
Glu	Xaa	Asp	Phe	Gln	Thr	Ala	Ala	Val	Pro	Val	Asp	Phe	Phe	Tyr	Ala	
610					615					620						
Lys	Gly	Ile	Leu	Glu	Ala	Xaa	Phe	Thr	Arg	Leu	Gly	Leu	Gln	Val	Thr	
625					630					635						640
Tyr	Thr	Ala	Thr	Ser	Glu	Ile	Xaa	Ser	Leu	His	Pro	Gly	Arg	Thr	Ala	
645					650					655						
Val	Ile	Ser	Leu	Gly	Asp	Gln	Val	Leu	Gly	Phe	Leu	Gly	Gln	Val	His	
660					665					670						
Pro	Val	Thr	Ala	Lys	Ala	Tyr	Asp	Ile	Pro	Glu	Thr	Tyr	Val	Ala	Glu	
675					680					685						
Leu	Asn	Leu	Ser	Ala	Ile	Glu	Gly	Ala	Leu	Gln	Pro	Ala	Val	Pro	Phe	
690					695					700						
Val	Glu	Ile	Thr	Arg	Phe	Pro	Ala	Val	Ser	Arg	Asp	Val	Ala	Phe	Leu	
705					710					715						720
Leu	Lys	Ala	Glu	Val	Thr	His	Gln	Ala	Val	Val	Asp	Ala	Ile	Gln	Ala	
725					730					735						
Ala	Gly	Val	Lys	Arg	Leu	Thr	Asp	Ile	Arg	Leu	Phe	Asp	Val	Phe	Ser	
740					745					750						
Gly	Glu	Lys	Leu	Gly	Leu	Gly	Met	Lys	Ser	Met	Ala	Tyr	Ser	Leu	Thr	
755					760					765						
Phe	Gln	Asn	Pro	Glu	Asp	Ser	Leu	Thr	Asp	Glu	Glu	Val	Ala	Arg		
770					775					780						

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 455 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

CGTATCGCTG ATAACTACAA AATCAAAAAA GGAAAAATCC GTGGTTTGGG GTCACCTTGGG    60
ATGATCTGTT CACTTGGTGA ATTGGGAATT TCTGACTCAG TTGTGCCTAA GGAATTCGCA    120
GATGGCATCC AAATCTTGCC TGAAGATGCC GTGCCAGGTG AGGAAGTCTT TTCTTACCTA    180
GACTTGGATG ATGAAATCAT CGAACTTTCC ATCACACCAA ACCGTGCAGA TGCCCTTTCT    240
ATGTGTGGAG TGGCTCACGA AGTGGCAGCC ATCTATGACA AGGCAGTCAA CTTTAAAAAAA    300
TTTACTCTAA CAGAACTAA TGAAGCTGCG GCAGATGCCC TTTCTGTCAG CATTGAGACA    360
GACAAGGCGC CTTACTATGC AGCTCGTATC TTGGACAATG TGAATATCGC ACCAAGTCCA    420
CAATGGTTGC AAAACCTTCT CATGAACGAA GCATC                                455

```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 151 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Arg Ile Ala Asp Asn Tyr Lys Ile Lys Lys Gly Lys Ile Arg Gly Leu
 1             5             10             15
Glu Ser Leu Gly Met Ile Cys Ser Leu Gly Glu Leu Gly Ile Ser Asp
      20             25             30
Ser Val Val Pro Lys Glu Phe Ala Asp Gly Ile Gln Ile Leu Pro Glu
      35             40             45
Asp Ala Val Pro Gly Glu Glu Val Phe Ser Tyr Leu Asp Leu Asp Asp
      50             55             60
Glu Ile Ile Glu Leu Ser Ile Thr Pro Asn Arg Ala Asp Ala Leu Ser
      65             70             75             80
Met Cys Gly Val Ala His Glu Val Ala Ala Ile Tyr Asp Lys Ala Val
      85             90             95
Asn Phe Lys Lys Phe Thr Leu Thr Glu Thr Asn Glu Ala Ala Ala Asp
      100            105            110
Ala Leu Ser Val Ser Ile Glu Thr Asp Lys Ala Pro Tyr Tyr Ala Ala
      115            120            125
Arg Ile Leu Asp Asn Val Thr Ile Ala Pro Ser Pro Gln Trp Leu Gln
      130            135            140
Asn Leu Leu Met Asn Glu Ala
145            150

```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1047 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

GGATCCCCCG GGCTGCAGGA ATTAAAAGCG CTTCGCGAAG AAACGCTGAC TAGCTTGAAG      60
CAGATTACTG CTGGAAATGA AAAAGAGATG CAAGATTTGC GTGTCTCTGT CCTTGGTAAA      120
AAGGGTTTCG TTAAGTAAAT CCTCAAAGGG ATGAAAGATG TTTCTGCTGA GATGCGTCCA      180
ATCATCGGGA AACACGTCAA TGAAGCTCGT GATGTCTTGA CAGCTGCTTT TGAAGAAACA      240
GCTAAGCTCT TGGAAGAAAA GAAAGTCGCG GCTCAACTGG CTAGCGAGAG TATCGATGTG      300
ACGCTTCCAG GTCGTCCAGT TCGGACTGGT CACCGTCACG TTTTGACACA AACCAGTGAA      360
GAAATCGAAG ATATCTTCAT CCGTATGGGT TATCAAGTCG TGGATGGTTT TGAAGTGGAG      420
CAAGACTACT ATAACCTTGA ACGTATGAAC CTTCCAAAAG ACCACCCAGC TCGTGATATG      480
CAGGATACTT TCTATATCAC TGAAGAAATC TTGCTCCGTA CCCACACGTC TCCAGTTCAG      540
GCACGTGCTA TGGATGCCCA TGATTTTCTT AAAGGTCCTT TGAAGATAAT CTCGCCAGGG      600
CGTGTCTTCC GTCGCGATAC GGACGATGCG ACCCACAGTC ACCAATTCCA CCAAATCGAA      660
GGCTTGGTAG TTGGGAAAAA TATCTCTATG GCTGATCTTC AAGGAACGCT TCAGTTGATT      720
GTCCAAAAAA TGTTTGGTGA AGAGCGTCAA ATTCGTTTGC GTCCATCTTA CTCCCATTTC      780
ACAGAGCCAT CTGTTGAGGT GGATGTTTCT TGCTTCAAAT GTGGTGGAGA AGGCTGTAAC      840
GTATGTAAGA AAACAGGTTG GATCGAAATT ATGGGGGCCG GTATGGTTCA CCCACGTGTC      900
CTTGAAATGA GTGGTATCGA TCGGACTGTA TACTCTGGCT TTGCCTTTGG TCTTGACAA      960
GAGCGTGTAG CTATGCTCCG TTATGGAATC AACGATATCC GTGGATTCTA CCAAGGAGAT     1020
GTCCGCTTCT CAGAACAGTT TAAATAA                                     1047

```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 348 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Gly Ser Pro Gly Leu Gln Glu Leu Lys Ala Leu Arg Glu Glu Thr Leu
1           5           10           15

```

```

Thr Ser Leu Lys Gln Ile Thr Ala Gly Asn Glu Lys Glu Met Gln Asp
      20                      25                      30
Leu Arg Val Ser Val Leu Gly Lys Lys Gly Ser Leu Thr Glu Ile Leu
      35                      40                      45
Lys Gly Met Lys Asp Val Ser Ala Glu Met Arg Pro Ile Ile Gly Lys
      50                      55                      60
His Val Asn Glu Ala Arg Asp Val Leu Thr Ala Ala Phe Glu Glu Thr
      65                      70                      75                      80
Ala Lys Leu Leu Glu Glu Lys Lys Val Ala Ala Gln Leu Ala Ser Glu
      85                      90                      95
Ser Ile Asp Val Thr Leu Pro Gly Arg Pro Val Ala Thr Gly His Arg
      100                     105                     110
His Val Leu Thr Gln Thr Ser Glu Glu Ile Glu Asp Ile Phe Ile Gly
      115                     120                     125
Met Gly Tyr Gln Val Val Asp Gly Phe Glu Val Glu Gln Asp Tyr Tyr
      130                     135                     140
Asn Phe Glu Arg Met Asn Leu Pro Lys Asp His Pro Ala Arg Asp Met
      145                     150                     155                     160
Gln Asp Thr Phe Tyr Ile Thr Glu Glu Ile Leu Leu Arg Thr His Thr
      165                     170                     175
Ser Pro Val Gln Ala Arg Ala Met Asp Ala His Asp Phe Ser Lys Gly
      180                     185                     190
Pro Leu Lys Ile Ile Ser Pro Gly Arg Val Phe Arg Arg Asp Thr Asp
      195                     200                     205
Asp Ala Thr His Ser His Gln Phe His Gln Ile Glu Gly Leu Val Val
      210                     215                     220
Gly Lys Asn Ile Ser Met Ala Asp Leu Gln Gly Thr Leu Gln Leu Ile
      225                     230                     235                     240
Val Gln Lys Met Phe Gly Glu Glu Arg Gln Ile Arg Leu Arg Pro Ser
      245                     250                     255
Tyr Phe Pro Phe Thr Glu Pro Ser Val Glu Val Asp Val Ser Cys Phe
      260                     265                     270
Lys Cys Gly Gly Glu Gly Cys Asn Val Cys Lys Lys Thr Gly Trp Ile
      275                     280                     285
Glu Ile Met Gly Ala Gly Met Val His Pro Arg Val Leu Glu Met Ser
      290                     295                     300
Gly Ile Asp Ala Thr Val Tyr Ser Gly Phe Ala Phe Gly Leu Gly Gln
      305                     310                     315                     320
Glu Arg Val Ala Met Leu Arg Tyr Gly Ile Asn Asp Ile Arg Gly Phe
      325                     330                     335
Tyr Gln Gly Asp Val Arg Phe Ser Glu Gln Phe Lys
      340                     345

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 197 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

CAATTCCACC AAATCGAAGG CTTGGTAGTT GGGAAAAATA TCTCTATGGC TGATCTTCAA      60
GGAACGCTTC AGTTGATTGT CCAAAAAATG TCTGGTGAAG AGCGTCAAAT TCGTTTGCCT      120
CCATCTTACT TCCCATTCAC ACACCCATCT GTTGAGGTGG ATGTTTCTTG CTTCAAATGT      180
GGTGGAGAAG GCTGTAA                                     197

```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 65 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```

Gln Phe His Gln Ile Glu Gly Leu Val Val Gly Lys Asn Ile Ser Met
 1           5           10           15
Ala Asp Leu Gln Gly Thr Leu Gln Leu Ile Val Gln Lys Met Ser Gly
          20           25           30
Glu Glu Arg Gln Ile Arg Leu Arg Pro Ser Tyr Phe Pro Phe Thr His
          35           40           45
Pro Ser Val Glu Val Asp Val Ser Cys Phe Lys Cys Gly Gly Glu Gly
          50           55           60
Cys
65

```

What is claimed is:

1. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:
 - (a) a polynucleotide having at least a 70% identity to a polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or 6;
 - (b) a polynucleotide which is complementary to the polynucleotide of (a);
 - (c) a polynucleotide having at least a 70% identity to a polynucleotide encoding the same mature polypeptide expressed by the pheS (beta) or pheS (alpha) gene contained in the *Streptococcus pneumoniae* of the deposited strain; and
 - (d) a polynucleotide comprising at least 15 sequential bases of the polynucleotide of (a), (b) or (c).
2. The polynucleotide of Claim 1 wherein the polynucleotide is DNA.
3. The polynucleotide of Claim 1 wherein the polynucleotide is RNA.
4. The polynucleotide of Claim 2 comprising the nucleic acid sequence set forth in SEQ ID NO:1.
5. The polynucleotide of Claim 2 comprising nucleotide 1 to 2034 set forth in SEQ ID NO:1 or nucleotide 1 to 915 set forth in SEQ ID NO:5.
6. The polynucleotide of Claim 2 which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or 6.
7. A vector comprising the polynucleotide of Claim 1.
8. A host cell comprising the vector of Claim 7.
9. A process for producing a polypeptide comprising: expressing from the host cell of Claim 8 a polypeptide encoded by said DNA.
10. A process for producing a pheS (beta) or pheS (alpha) polypeptide or fragment comprising culturing a host of claim 8 under conditions sufficient for the production of said polypeptide or fragment.
11. A polypeptide comprising an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ID NO:2 or 6.
12. A polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2 or 6.
13. An antibody against the polypeptide of claim 11.
14. An antagonist which inhibits the activity or expression of the polypeptide of claim 11.

15. A method for the treatment of an individual in need of pheS (beta) or pheS (alpha) polypeptide comprising: administering to the individual a therapeutically effective amount of the polypeptide of claim 11.

16. A method for the treatment of an individual having need to inhibit pheS (beta) or pheS (alpha) polypeptide comprising: administering to the individual a therapeutically effective amount of the antagonist of Claim 14.

17. A process for diagnosing a disease related to expression or activity of the polypeptide of claim 11 in an individual comprising:

- (a) determining a nucleic acid sequence encoding said polypeptide, and/or
- 10 (b) analyzing for the presence or amount of said polypeptide in a sample derived from the individual.

18. A method for identifying compounds which interact with and inhibit or activate an activity of the polypeptide of claim 11 comprising:

contacting a composition comprising the polypeptide with the compound to be screened
15 under conditions to permit interaction between the compound and the polypeptide to assess the interaction of a compound, such interaction being associated with a second component capable of providing a detectable signal in response to the interaction of the polypeptide with the compound;

and determining whether the compound interacts with and activates or inhibits an
20 activity of the polypeptide by detecting the presence or absence of a signal generated from the interaction of the compound with the polypeptide.

19. A method for inducing an immunological response in a mammal which comprises inoculating the mammal with pheS (beta) or pheS (alpha) polypeptide of claim 11, or a fragment or variant thereof, adequate to produce antibody and/or T cell immune
25 response to protect said animal from disease.

20. A method of inducing immunological response in a mammal which comprises delivering a nucleic acid vector to direct expression of pheS (beta) or pheS (alpha) polypeptide of claim 11, or fragment or a variant thereof, for expressing said pheS (beta) or pheS (alpha) polypeptide, or a fragment or a variant thereof *in vivo* in order to induce an
30 immunological response to produce antibody and/ or T cell immune response to protect said animal from disease.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/06876

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/190.1; 435/6, 69.1, 252.3, 320.1; 530/350, 387.1, 388.4; 536/23.7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, CA, EMBASE, BIOSIS

search terms: Streptococcus, PheS, phenylalanyl-tRNA synthetase

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BRAXHAGE. A.A. et al. Structure and Nucleotide Sequence of the Bacillus subtilis Phenylalanyl-tRNA Synthetase Genes. Biochimie. 1990, Vol. 72, pages 725-734, see entire document.	1-20
A	KREUTZER, R. et al. Structure of the Phenylalanyl-tRNA Synthetase Genes from Thermus thermophilus HB8 and Their Expression in E. coli. Nucleic Acids Research. 1992, Vol 20, No. 1, pages 4173-4178, see entire document.	1-20

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A		document defining the general state of the art which is not considered to be of particular relevance
* E		earlier document published on or after the international filing date
* L		document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
* O		document referring to an oral disclosure, use, exhibition or other means
* P		document published prior to the international filing date but later than the priority date claimed
	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
	* &	document member of the same patent family

Date of the actual completion of the international search 22 JUNE 1997	Date of mailing of the international search report 15 AUG 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer ANTHONY C. CAPUTA Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/06876

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 39/09; C12N 5/10; 9/00; 15/31; C12Q 1/14; C12P 21/00; C07K 14/315, 16/12

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/190.1; 435/6, 69.1, 252.3, 320.1; 530/350, 387.1, 388.4; 536/23.7